Evidence map›Paper›PMID 40837040›Full record

ArticleSmall science2025

Hyaluronic Acid-Decorated Liposomes for the Intrapulmonary Delivery of Imatinib: A Targeted Treatment for Postinflammatory Pulmonary Fibrosis.

Sara Bozzini, Valeria Bincoletto, Laura Pandolfi, Roberta Fusco, Rosanna Di Paola, Salvatore Cuzzocrea, Ilaria Andreana, Barbara Rolando, Eleonora Bozza, Cecilia Bagnera and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Advances in Inhaled Nanoparticle Drug Delivery for Pulmonary Disease Management.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sara BozziniSecond Department of Anesthesia and Intensive Care Fondazione IRCCS Policlinico San Matteo 27100 Pavia Italy.
Valeria BincolettoDepartment of Drug Science and Technology University of Turin Via P. Giuria 9 10125 Turin Italy.
Laura PandolfiLaboratory of Respiratory Disease Section of Cell Biology UOS Transplant Center Fondazione IRCCS Policlinico San Matteo 27100 Pavia Italy.
Roberta FuscoDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences University of Messina 98166 Messina Italy.
Rosanna Di PaolaDepartment of Veterinary Science University of Messina 98168 Messina Italy.
Salvatore CuzzocreaDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences University of Messina 98166 Messina Italy.
Ilaria AndreanaDepartment of Drug Science and Technology University of Turin Via P. Giuria 9 10125 Turin Italy.
Barbara RolandoDepartment of Drug Science and Technology University of Turin Via P. Giuria 9 10125 Turin Italy.
Eleonora BozzaDepartment of Paediatric Oncoematology/Cell Factory Fondazione IRCCS Policlinico San Matteo 27100 Pavia Italy.
Cecilia BagneraDepartment of Paediatric Oncoematology/Cell Factory Fondazione IRCCS Policlinico San Matteo 27100 Pavia Italy.
Manuela MontiResearch Center for Regenerative Medicine Fondazione IRCCS Policlinico San Matteo 27100 Pavia Italy.
Barbara StellaDepartment of Drug Science and Technology University of Turin Via P. Giuria 9 10125 Turin Italy.
Federica MeloniDepartment of Cardio-Thoracic, Vascular Sciences and Public Health University of Padua 35128 Padua Italy.ORCID https://orcid.org/0000-0003-4014-0617
Silvia ArpiccoDepartment of Drug Science and Technology University of Turin Via P. Giuria 9 10125 Turin Italy.ORCID https://orcid.org/0000-0002-4754-6591

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanotechnology allows drugs to be delivered locally and specific cells to be targeted, leading to a promising new therapeutic approach for interstitial lung fibrosis. Hyaluronic acid (HA)-decorated imatinib-loaded liposomes (LIP-HA44700-Im) are developed to target CD44 positive cells for the inhalation treatment of fibrogenic lung disorders. LIP-HA44700-Im are assessed for their uptake and biological activity on respiratory effectors that are related to CD44 expression and compared to undecorated liposomes (LIP). LIP-HA44700-Im uptake is significantly higher than that of LIP, and most of the internalized LIP-HA44700-Im are colocalized with cellular endosomes. LIP-HA44700-Im also reduce lung fibroblasts viability. After 24 h, LIP-HA44700-Im are able to impair collagen 1a1 release and c-Abl phosphorylation. Based on in vitro data, it has been assessed whether the intratracheal administration of LIP-HA44700-Im is able to prevent lung fibrosis in a mouse bleomycin model. The local administration of LIP-HA44700-Im is associated with a significant decrease in alveolar inflammation, lung fibrosis, collagen deposition, and TGF-β expression. LIP-HA44700-Im target and deliver imatinib to lung pathogenic cells in vitro and represent a promising therapeutic option for the local treatment of fibrogenic lung disorders, although further development is required. These in vivo results confirm the validity of targeted nano-based treatment for inflammatory-driven lung fibrogenesis.

Indexed as

chronic lung allograft dysfunctionsimatinibinterstitial lung diseasesliposomes

Identifiers

PMID40837040
PMCPMC12362731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.